CANCER AND LEUKEMIA GROUP B

爱荷华州的大学作为癌症和白血病 B组在未来五年的目标是：1）维持我们的模式， 增加对CALGB试验的应计费用; 2）继续开发 爱荷华州大学的临床和基础科学领域， 将为该集团带来创新的临床试验;以及3）增加 在爱荷华州的农村地区进一步分支机构，使国家的最先进的癌症 可以为这些小到无法支持癌症的社区提供护理， 程序. 在过去四年的赠款，我们的应计费用从98/年， 148/年 我们在上一次拨款中的既定目标是 每年100多名患者。 在1992年的头三个月， 累计52例患者（208/年）。 我们希望平均175例患者/年 在这段时间里， 目前或不久将开放的CALGB试验由大学发起， 爱荷华州包括：1）皮下IL-2在晚期小细胞肺癌中的应用 在爱荷华州大学进行了sIL-2受体和LAK细胞的检测 产生;和2）使用干细胞以允许多个周期的 强化化疗，无需自体骨髓移植。 基本 具有未来CALGB试验潜力的科学计划是：1） 抗淋巴瘤细胞双特异性单克隆抗体的研制 抗原; 2）HMG-CoA还原酶抑制剂阻断的体外研究 RAS表达所必需的法尼基化和香叶基化;以及3） 使用PCNA作为发展的中间标记物， 肺部肿瘤 来自爱荷华州大学的医学肿瘤学家现在正在为芒特 爱荷华州的普莱森特和爱荷华州的马斯卡廷。 在梅森市有分支机构 达文波特和滑铁卢。 我们正在探索进一步的外展计划， 城镇太小，无法支持全职肿瘤学家和附属机构， 较大的城镇将CALGB计划带到服务不足的农村地区， 状态 这将使少数民族人口在以下城镇增加， 马斯卡廷和农村地区的穷人接受这些方案的服务。 为 进行护理的医生将是爱荷华州大学的教师，我们 将能够在这些领域提供高质量的护理和数据。

The goals of the University of Iowa as members of the Cancer and Leukemia Group B over the next five years are: 1) to sustain our pattern of increasing accrual to CALGB trials; 2) to continue to develop programs in both clinical and basic science areas at the University of Iowa which will lead to innovative clinical trials for the group; and 3) to add further affiliates in rural areas in Iowa so that state-of-the-art cancer care can be brought to these communities too small to support cancer programs. Over the last four years of the grant, our accrual went from 98/year to 148/year. Our stated goal in the last grant was to accrue approximately 100+ patients per year. In the first three months of 1992 we have accrued 52 patients (a rate of 208/yr). We hope to average 175 pts/year in this grant period. Current or soon to be open CALGB trials initiated from the University of Iowa include: 1) subcutaneous IL-2 in advanced small cell lung cancer with assay at the University of Iowa of sIL-2 receptor and LAK cell generation; and 2) the use of stem cells to allow multiple cycles of intensive chemotherapy without autologous bone marrow transplant. Basic science programs with potential for future CALGB trials are: 1) the development of bispecific monoclonal antibodies to lymphoma cell antigens; 2) studies in vitro of HMG-CoA reductase inhibitors to block the farnesylation and geranylation necessary for RAS expression; and 3) the use of PCNA as an intermediate marker for the development of neoplasia in the lung. Medical oncologists from the University of Iowa are now serving Mount Pleasant, Iowa and Muscatine, Iowa. Affiliates are going in Mason City, Davenport, and Waterloo. We are exploring further outreach programs in towns too small to ever support a fulltime oncologist and affiliates in larger towns to bring CALGB programs to underserved rural areas of the state. This will allow accrual of minority populations in towns such as Muscatine and the poor in rural areas served by these programs. As the physicians carrying out the care will be University of Iowa faculty, we will be able to provide quality care and data in these areas.